Summary of Contents

Proof of False Representation or Implication
That Debt Collector is Vouched for, Bonded
by, or Affiliated with United States or Any
State in Violation of Fair Debt Collection
Practices Act (15 U.S.C.A. § 1692e(1)) ............ 1

Proof of Fraudulent Representation on Internet
Concerning Consumer Goods ......................... 97

Proof That Small Business is Owned and
Controlled by Socially and Economically
Disadvantaged Person Under Small Business
Act § 8(a) (15 U.S.C.A. § 637(a)) ..................... 173

Proof of Reverse False Claim Pursuant to State
False Claims Act ........................................ 311

Proof of Liability for Injury Caused by
Compounded Drug ...................................... 417
Publisher
Jean E. Maess, J.D.

Publication Editor
Tim A. Thomas, J.D.

Legal Editors
Richard J. Arneson, J.D.  Jason R. Espinosa, J.D.
Jason B. Binimow, J.D.   Molly McNulty, J.D.
PROOF OF FALSE REPRESENTATION OR IMPLICATION THAT DEBT COLLECTOR IS VOUCHED FOR, BONDED BY, OR AFFILIATED WITH UNITED STATES OR ANY STATE IN VIOLATION OF FAIR DEBT COLLECTION PRACTICES ACT (15 U.S.C.A. § 1692e(1))

Malla Pollack, J.D.*

TABLE OF CONTENTS

    Scope
    Research References
    Index

ARTICLE OUTLINE

I. LEGAL BACKGROUND

    A. IN GENERAL

    § 1 Introduction—Scope of article
    § 2 Procedural matters
    § 3 Remedies

    B. FAIR DEBT COLLECTION PRACTICES ACT

    § 4 Overview

---

*Malla Pollack graduated from the Benjamin N. Cardozo School of Law, Yeshiva University summa cum laude and number one in her class after earning a Master’s Degree in Library Science with honors. She clerked for Charles Proctor Sifton, E.D.N.Y., and Ruth Bader Ginsburg, D.C. Cir. (now Associate Justice of the U.S. Supreme Court), spent several years litigating intellectual property and related matters at a national law firm, and taught intellectual property and other subjects at several law schools. She has authored numerous articles on intellectual property and filed a number of amicus briefs in intellectual property matters with federal courts, including the United States Supreme Court. With Louis Altman, she is coauthor of Callmann on Unfair Competition, Trademarks, and Monopolies (4th ed. West). Many of her academic publications are available at http://works.bepress.com/malla_pollack/.

1
§ 5 Debt collection practices regulated by Act
§ 6 Debt collectors subject to Act
§ 7 Actions “in connection with” debt collection

C. FALSE, DECEPTIVE, OR MISLEADING REPRESENTATIONS

§ 8 False, deceptive, or misleading representations—
   Generally
§ 9 Standard of evaluation
§ 10 Materiality
§ 11 Falsity or misleading nature as issue of fact or law
§ 12 Representation regarding government relationship—Section 1692e(9)
§ 13 —Section 1692e(1)
§ 14 Extrinsic evidence as to construction of dunning communication
§ 15 —Expert opinion
§ 16 Extrinsic evidence—Surveys

II. CHECKLISTS

§ 17 Damages
§ 18 Elements of proof

III. MODEL DOCUMENTS

A. HYPOTHETICAL

§ 19 Background facts
§ 20 Text of relevant dunning letter
§ 21 Graphics of relevant dunning letter

B. MODEL MOTION TO DISMISS

§ 22 Excerpts from defendant’s Fed. R. Civ. P. 12(b)(6) motion
§ 23 Plaintiff’s opposition to defendant’s motion to dismiss—Excerpts from memorandum of law
§ 24 —Affidavit of H.I. as to nature and extent of defendant’s debt collection operations
§ 25 —Affidavit of J.K. (named plaintiff in class action)
§ 26 —Affidavit of L.M. (named plaintiff in class action)
§ 27 —Affidavit of Dr. F.R. (expert retained by plaintiff)
DEBT COLLECTOR REPRESENTATION

C. MODEL MOTION TO EXCLUDE EXTRINSIC EVIDENCE

§ 28 Hypothetical extrinsic evidence
§ 29 —Control letter
§ 30 Excerpts from defendant’s motion to exclude
§ 31 Excerpts from plaintiff’s opposition to defendant’s motion to exclude

IV. PROOF OF FALSE REPRESENTATION OR IMPLICATION THAT DEBT COLLECTOR IS VOUCHED FOR, BONDED BY, OR AFFILIATED WITH UNITED STATES OR ANY STATE IN VIOLATION OF FAIR DEBT COLLECTION PRACTICES ACT (15 U.S.C.A. § 1692e(1))

A. TRIAL PROCEDURE

§ 32 Trial court rulings in hypothetical case

B. TESTIMONY OF NAMED PLAINTIFF

§ 33 Testimony of A.A.—Elements of statutory violation
§ 34 —Cross examination

C. TESTIMONY OF DEFENDANT’S MANAGER AS HOSTILE WITNESS

§ 35 Testimony of S.T. as hostile witness—Elements of statutory violation
§ 36 Testimony of S.T.—Examination by counsel for defense

D. TESTIMONY OF PLAINTIFF’S EXPERT WITNESS

§ 37 Direct testimony of Dr. F.R.—Credentials
§ 38 —Survey universe and sample
§ 39 —Screening test
§ 40 —Survey and control questions
§ 41 —Tabulation, verification, and results
§ 42 Cross-examination of Dr. F.R.
§ 43 Redirect examination of Dr. F.R.
PROOF OF FRAUDULENT REPRESENTATION ON INTERNET CONCERNING CONSUMER GOODS

Laura Hunter Dietz, J.D.*

TABLE OF CONTENTS
Scope
Research References
Index

ARTICLE OUTLINE

I. LEGAL BACKGROUND

A. IN GENERAL

§ 1 Introduction; scope of article
§ 2 Overview of claims under state consumer protection acts
§ 3 Overview of tort claims for fraudulent representation

B. CAUSE OF ACTION FOR FRAUDULENT REPRESENTATION ON INTERNET CONCERNING CONSUMER GOODS

§ 4 Necessity of stating allegations of fraud with particularity
§ 5 Private rights of action under state consumer protection acts
§ 6 Injury as element of private right of action under consumer protection laws
§ 7 Requirement of causal connection between fraudulent representation and loss or injury

*Ms. Dietz received her J.D. from Suffolk University’s Law School in 1991. An active member of the Massachusetts bar, she has worked in legal publishing for over 20 years and has written for various publications in addition to Proof of Facts, including American Law Reports (Federal); American Jurisprudence 2d; Corpus Juris Secundum; Federal Procedure, Lawyers Edition; and several state jurisprudences.
§ 8 Fraudulent or deceptive pricing
§ 9 True statement as actionable when it is likely to mislead or deceive
§ 10 Negligent misrepresentation
§ 11 Common law claims
§ 12 Class actions
§ 13 Construction of consumer protection laws

C. HYPOTHETICAL
§ 14 Model fact pattern used in pleadings, discovery, and examination

II. DAMAGES AND OTHER REMEDIES
§ 15 Remedies in common law actions for fraudulent misrepresentation
§ 16 Availability of equitable relief
§ 17 —Injunction against future violations of consumer protection laws
§ 18 Statutory damages
§ 19 Restitution and rescission
§ 20 Attorney’s fees

III. ELEMENTS OF PROOF
§ 21 Elements of proof of fraudulent representation on Internet concerning consumer goods—Common law
§ 22 —State consumer protection statutes

IV. MODEL PLEADINGS, MOTIONS, AND DISCOVERY; CHECKLISTS
A. PLEADINGS: MOTIONS TO DISMISS
§ 23 Sample complaint
§ 24 Checklist—Possible grounds for defense motion to dismiss
§ 25 —Possible affirmative defenses

B. DISCOVERY
§ 26 Sample written interrogatories from plaintiff to defendant
§ 27 Sample request from plaintiff to defendant for production of documents and tangible things
INTERNET CONSUMER GOODS FRAUD

§ 28 Sample written interrogatories from defendant to plaintiff

§ 29 Sample request from defendant to plaintiff for production of documents and tangible things

C. SUMMARY JUDGMENT

§ 30 Checklist—Content of plaintiff’s motion for summary judgment on issue of liability

§ 31 —Content of defense motion for summary judgment on issue of liability

V. PROOF OF FRAUDULENT REPRESENTATION ON INTERNET CONCERNING CONSUMER GOODS

§ 32 Direct examination of plaintiff on issue of ascertainable loss

§ 33 Cross-examination of plaintiff on issue of ascertainable loss

§ 34 Direct examination by plaintiff of defendant’s employee as to defendant’s intent to use its pricing methods to induce consumers to purchase goods

§ 35 Cross-examination by defense of defendant’s employee as to defendant’s intent to use its pricing methods to induce consumers to purchase goods

§ 36 Direct examination by plaintiff of defendant’s employee as to defendant’s deceptive pricing

§ 37 Direct examination by defense of defendant’s employee as to defendant’s deceptive pricing

§ 38 Direct examination of plaintiff as to reliance on defendant’s fraudulent pricing

§ 39 Cross-examination by defense of plaintiff as to reliance on defendant’s fraudulent pricing

Scope

This article presents an overview of the law of fraudulent representation, to provide the practitioner with basic information as to what is required in the proof and/or defense of a claim of fraudulent representation concerning the sale of consumer goods over the Internet.
PROOF THAT SMALL BUSINESS IS OWNED
AND CONTROLLED BY SOCIALLY AND
ECONOMICALLY DISADVANTAGED PERSON
UNDER SMALL BUSINESS ACT § 8(a) (15
U.S.C.A. § 637(a))

Anne M. Payne, J.D.*

TABLE OF CONTENTS
Scope
Research References
Index

ARTICLE OUTLINE

I. BACKGROUND
§ 1 Introduction
§ 2 Scope

II. LEGAL BACKGROUND
A. IN GENERAL
§ 3 Federal programs relating to “social and economic
disadvantage,” generally
§ 4 Purpose of federal programs to benefit socially and
economically disadvantaged firms

*Anne M. Payne has practiced law for over 30 years, with primary
emphasis on real property, financial services, commercial transactions,
and corporate law. After a successful career in private practice, she began
her own firm in 1994, specializing in legal research and appellate consult-
ing. She has written extensively for over 20 years on a broad variety of
topics and is a coauthor of the treatises “Modern New York Discovery 2d”
and “New York Insurance Law” (part of the New York Practice Series).
She taught Business Law for seven years at Hartwick College and has
over 10 years of experience as a public school board member.
B. SMALL BUSINESS ACT PROGRAM FOR SOCIALLY AND ECONOMICALLY DISADVANTAGED FIRMS

1. In General

§ 5 Small Business Act, generally

2. Provisions Governing Socially and Economically Disadvantaged Businesses

§ 6 Section 8(a) business development programs; generally

§ 7 Purpose

§ 8 Validity

3. Qualification as Socially and Economically Disadvantaged Small Business
   a. In General

§ 9 Small business qualification, generally

§ 10 Self-designation as small disadvantaged business

   b. Section 8(a) Business Development Program Eligibility

§ 11 Certification under section 8(a) as socially and economically disadvantaged, generally

§ 12 —Decision; review; appeals

§ 13 —Termination; suspension

§ 14 Social disadvantage eligibility requirements

§ 15 Economic disadvantage eligibility requirements

§ 16 Ownership eligibility requirements

§ 17 Control eligibility requirements

§ 18 Size eligibility requirements

§ 19 Potential for success requirement

§ 20 Other eligibility requirements; good character; prior participant ban; entity-specific rules

C. PROCEDURAL ISSUES

§ 21 Context in which challenge to status as “socially and economically disadvantaged” arises

§ 22 Standing to sue

§ 23 Who may be sued

§ 24 Administrative proceedings; due process
CONTROL OF SMALL BUSINESS

§ 25 Commencement of action
§ 26 Jurisdiction and venue
§ 27 Motions
§ 28 Standard of review of SBA decision
§ 29 Decision; order; judgment

III. ELEMENTS

§ 30 Preconditions; generally
§ 31 Preconditions—Exhaustion of administrative remedies
§ 32 Proof of eligibility or ineligibility for section 8(a) business development program
§ 33 Relief; declaratory judgment; injunctive relief; preliminary injunction

IV. PLEADINGS

§ 34 Complaint
§ 35 Sample complaint—Wrongful denial of certification as socially and economically disadvantaged
§ 36 —Allegations—Erroneous grant of certification as socially and economically disadvantaged

V. CASE INVESTIGATION AND DISCOVERY

A. IN GENERAL

§ 37 Scope of information sought through discovery and investigation
§ 38 Sample deposition questions
§ 39 Sample notice to produce
§ 40 Freedom of Information or Privacy Act requests; public records access

B. OBTAINING PARTICULAR INFORMATION

§ 41 Agency decision denying application or terminating participation
§ 42 Application for certification; supporting documents
§ 43 —SBA’s checklist of supporting documents
§ 44 Annual review document checklist
§ 45 Financial information
§ 46 Protests filed by losing bidder or competing contractor
§ 47 Protests filed by contracting officer
§ 48 Hotline complaints
§ 49 Worksheets used in making calculations

VI. PROOF OF ELIGIBILITY AS SOCIALLY AND ECONOMICALLY DISADVANTAGED BUSINESS

A. IN GENERAL
§ 50 Hypothetical fact situation
§ 51 Burden and quantum of proof
§ 52 —Presumptions
§ 53 Evidence; record in proceedings below
§ 54 —Objections
§ 55 —Expert or opinion testimony; qualification of witness

B. PROOF THAT BUSINESS IS “SMALL BUSINESS CONCERN”
§ 56 Size, generally; sample testimony
§ 57 Size as affected by affiliation with other businesses; sample testimony

C. PROOF THAT BUSINESS IS “OWNED” OR “CONTROLLED” BY PARTICULAR INDIVIDUAL
§ 58 Documentary evidence of unconditional and direct ownership; sample testimony
§ 59 Sufficiency of percentage or degree of ownership—Corporation; sample testimony
§ 60 —Partnership; sample testimony
§ 61 Control of applicant business; sample testimony
§ 62 Control of applicant business—Interlocking ownership with larger business; sample testimony

D. PROOF THAT INDIVIDUAL OWNER IS SOCIALLY AND ECONOMICALLY DISADVANTAGED

1. In General
§ 63 Lack of one type of disadvantage as precluding qualification; sample testimony
§ 64 Effect of protest or complaint on term of continued eligibility or participation; sample testimony

2. Proof of Socially Disadvantaged Status

§ 65 Being subjected to racial or ethnic prejudice or cultural bias; sample testimony

§ 66 Being subjected to racial or ethnic prejudice or cultural bias—Negative impact on entry into, or advancement in, business; sample testimony

§ 67 —Rebuttal of alternate basis for action taken; sample testimony

§ 68 Without regard to individual qualities; sample testimony

§ 69 Stemming from circumstances beyond individual's control; sample testimony

§ 70 Presumption of social disadvantage

§ 71 —Holding oneself out as member of designated group and identification as such by others; sample testimony

§ 72 —Rebuttal of presumption; sample testimony

3. Proof of “Economically Disadvantaged” Status

§ 73 Impaired ability to compete; thresholds; rebuttal; sample testimony

E. PROOF OF MISCELLANEOUS OTHER ELEMENTS

§ 74 Good moral character

§ 75 Potential for success; sample testimony

F. MISREPRESENTATION IN APPLICATION

§ 76 Misrepresentation or omission as to qualified status—In application or renewal; of facts affecting eligibility; sample testimony

§ 77 —To obtain contract or preference

VII. RELIEF

§ 78 Injunctive relief; reinstatement in SBA program

§ 79 Remand to SBA

§ 80 Lien on payments made

§ 81 Qualified immunity from suit
PROOF OF REVERSE FALSE CLAIM
PURSUANT TO STATE FALSE CLAIMS ACT

Malla Pollack, J.D.*

TABLE OF CONTENTS

Scope
Research References
Index

ARTICLE OUTLINE

I. LEGAL BACKGROUND

§ 1 Introduction—Scope of article
§ 2 False Claims Acts—Purpose of qui tam suits
§ 3 —Direct false claims
§ 4 —Reverse false claim
§ 5 —Statutory language
§ 6 Construing state statutes
§ 7 Procedure in qui tam case—Overview
§ 8 —State's power to dismiss
§ 9 —State's power to settle
§ 10 —Other issues
§ 11 Effect of prior public disclosure of allegations or transactions upon which False Claims Act suit is based

---

*Malla Pollack graduated from Benjamin N. Cardozo School of Law, Yeshiva University summa cum laude and number one in her class after earning a Master’s Degree in Library Science with honors. She clerked for Charles Proctor Sifton, E.D.N.Y., and Ruth Bader Ginsburg, D.C. Cir. (now Associate Justice of the U.S. Supreme Court), spent several years litigating intellectual property and related matters at a national law firm, and taught intellectual property and other subjects at several law schools. She has authored numerous articles on intellectual property and filed a number of amicus briefs in intellectual property matters with federal courts, including the United States Supreme Court. With Louis Altman, she is coauthor of Callmann on Unfair Competition, Trademarks, and Monopolies (4th ed. West). Many of her academic publications are available at http://works.bepress.com/malla_pollack/.

311
§ 12 —Where relator is “original source” of information
§ 13 Other bars on false claims actions
§ 14 Statute of limitations
§ 15 Key terms—“Obligation”
§ 16 —“Knowingly”
§ 17 Theory of implied certification
§ 18 Specificity of pleading
§ 19 Alternative sources of discovery
§ 20 Remedies available against defendant
§ 21 Case law regarding computations of monies assessed against defendant
§ 22 Rewards available to relator

II. DAMAGES

A. ASSESSED AGAINST DEFENDANT
§ 23 Items assessed against defendant

B. REWARD TO RELATOR
§ 24 Reward to relator, generally

III. ELEMENTS OF PROOF
§ 25 Elements of proof, generally

IV. PROOF OF REVERSE FALSE CLAIMS ACT ALLEGATION

A. HYPOTHETICAL CASE
§ 26 Hypothetical facts
§ 27 Procedure before trial
§ 28 Trial procedure

B. TESTIMONY OF PLAINTIFF/RELATOR
§ 29 Examination by counsel for relator—Background of investigation
§ 30 —Investigation
§ 31 —Interaction with Attorney General’s office
§ 32 Examination by counsel for Family Bank
§ 33 Examination by counsel for Attorney General’s office
STATE FALSE CLAIMS ACTS

C. TESTIMONY OF MANAGER OF ASSISTED LIVING CENTER

§ 34 Examination by counsel for relator—Business records and other background information
§ 35 —Residents who may have bought CIs
§ 36 Examination by counsel for Family Bank
§ 37 Examination by counsel for Attorney General’s office

D. TESTIMONY OF RELATOR’S PRIVATE INVESTIGATOR

§ 38 Examination by counsel for relator
§ 39 Examination by counsel for Family Bank
§ 40 Examination by counsel for Attorney General’s office

E. TESTIMONY OF RELATOR’S FORENSIC ACCOUNTANT

§ 41 Examination by counsel for relator
§ 42 Examination by counsel for Family Bank
§ 43 Examination by counsel for Attorney General’s office

F. TESTIMONY OF OFFICER OF FAMILY BANK OF Z

§ 44 Examination by counsel for relator
§ 45 Examination by counsel for Family Bank
§ 46 Examination by counsel for Attorney General’s office

G. TESTIMONY OF PRIVATE INVESTIGATOR FOR FAMILY BANK OF Z

§ 47 Examination by counsel for Family Bank
§ 48 Examination by counsel for Attorney General’s office
§ 49 Examination by counsel for relator

H. TESTIMONY OF INVESTIGATOR FROM ATTORNEY GENERAL’S OFFICE

§ 50 Examination by counsel for Attorney General’s office
§ 51 Examination by counsel for relator
§ 52 Examination by counsel for Family Bank

Scope
This article discusses and illustrates a qui tam suit filed by a private individual as relator for a state (or division of a state) against a third party who is alleged to have knowingly submitted false documentation to that state (or division of that state) for the purpose of obtaining payment from the state (or division of the state).

Research References

West’s Key Number Digest
States ☞188

A.L.R. Library
A.L.R. Index, False Claims Act
West’s A.L.R. Digest, States ☞188
Construction and application of “public disclosure” and “original source” jurisdictional bars under 31 U.S.C.A. sec. 3730(e)(4) (civil actions for false claims), 117 A.L.R. Fed. 263

Legal Encyclopedias
Am. Jur. 2d, False Pretenses
C.J.S., United States

Treatises and Practice Aids
50 State Statutory Surveys: Health Care: Fraud and Abuse; State Qui Tam Laws, 0100 SURVEYS 2
False Claims Act: Fraud Against the Government, State False Claims Laws

Trial Strategy

Forms
Am. Jur. Pleading and Practice Forms, United States
Federal Procedural Forms, Government Contracts

Law Reviews and Other Periodicals
Chunias, Hunter, Raphael, Qui Tam Suits and the Civil False Claims Act, BT MA-CLE 16-1 (2016)
PROOF OF LIABILITY FOR INJURY CAUSED
BY COMPOUNDED DRUG

Monique C.M. Leahy, J.D.*

TABLE OF CONTENTS

Scope
Research References
Index

ARTICLE OUTLINE

I. LEGAL BACKGROUND
   A. IN GENERAL
      § 1 Introduction and scope
      § 2 Compounded drugs
      § 3 Statutory and regulatory control of compounded drugs
      § 4 —Federal authority

*Ms. Leahy is nationally recognized as a premier authority on medical and personal injury litigation, employment and workers’ compensation issues, internet law, and state-specific civil litigation in her over 90 published works that include over 40 practitioner publications. Ms. Leahy’s recently published works include: Multiple Concussion Injury, 127 Am. Jur. Proof of Facts 3d 1; Proof of Neurotoxic Injury in Civil and Criminal Actions, 56 Am. Jur. Proof of Facts 3d 221; Medical Malpractice Liability for Failure to Diagnose and Treat Post Traumatic Stress Disorder (PTSD), 149 Am. Jur. Proof of Facts 3d 201; Proof of Negligence by Health Care Providers for Blooddraws and Transfusions, 143 Am. Jur. Proof of Facts 3d 223; Proof of Malpractice Liability for Prescription of Painkiller Causing Injury or Death, 142 Am. Jur. Proof of Facts 3d 149. She is the Principal of Wordsworth Publishing and is an attorney licensed in Washington, Missouri, and Kansas. Wordsworth publishes an online monthly medical litigation report, Medical Law Perspectives, providing in-depth medical litigation information and news. While in private practice, Ms. Leahy focused on litigation as well as corporate transactions and telecommunications law. She is a former managing editor at Lawyers Cooperative Publishing/Research Institute of America, a subsidiary of Thomson Reuters.
§ 5 —State regulation
§ 6 Investigation of injury from compounded drug—
    Sample report of consulting expert
§ 7 —Checklist
§ 8 Potentially liable persons and entities
§ 9 Insurance

B. ADMISSION OF EVIDENCE
§ 10 Admissibility of evidence in action involving injury
    from compounded drug
§ 11 Expert testimony

C. HYPOTHETICALS
§ 12 Model medical malpractice fact pattern for use in
    pleadings, discovery, and examinations
§ 13 Model products liability fact pattern for use in
    pleadings, discovery, and examinations

II. DAMAGES AND OTHER REMEDIES
§ 14 Damages, generally
§ 15 Damages in cases involving compounded drugs
§ 16 Damages; checklist
§ 17 Injunction

III. ELEMENTS OF PROOF
§ 18 Medical malpractice, generally
§ 19 Malpractice involving compounded drugs
§ 20 Medical malpractice; checklist
§ 21 Products liability, generally
§ 22 Products liability involving compounded drugs
§ 23 Products liability; checklists

IV. MODEL PLEADINGS, MOTIONS, AND
    DISCOVERY
A. PLEADINGS
§ 24 Pleadings; affirmative defenses checklists
§ 25 Sample complaint—Against pharmacy and
    pharmacist
§ 26 —Including claim for loss of consortium
§ 27 —Negligence and strict products liability
B. PRETRIAL MOTIONS

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 28</td>
<td>Motion for summary judgment</td>
</tr>
<tr>
<td>§ 29</td>
<td>Motion to dismiss; motion for judgment on pleadings</td>
</tr>
<tr>
<td>§ 30</td>
<td>Sample motions in limine</td>
</tr>
</tbody>
</table>

C. DISCOVERY

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 31</td>
<td>Discovery, generally</td>
</tr>
<tr>
<td>§ 32</td>
<td>Interrogatories—generally</td>
</tr>
<tr>
<td>§ 33</td>
<td>—For use by plaintiff—Defendant physician’s qualifications and experience</td>
</tr>
<tr>
<td>§ 34</td>
<td>—Existence of duty on defendant physician’s part</td>
</tr>
<tr>
<td>§ 35</td>
<td>—Defendant physician’s version of events</td>
</tr>
<tr>
<td>§ 36</td>
<td>—For use by defendant physician—Plaintiff’s version of events</td>
</tr>
<tr>
<td>§ 37</td>
<td>—Plaintiff’s injuries and damages</td>
</tr>
<tr>
<td>§ 38</td>
<td>—Plaintiff’s medical history</td>
</tr>
<tr>
<td>§ 39</td>
<td>—Plaintiff’s employment history</td>
</tr>
<tr>
<td>§ 40</td>
<td>—Plaintiff’s involvement in other litigation</td>
</tr>
<tr>
<td>§ 41</td>
<td>Deposition—Sample questions to be asked of defendant in products liability action</td>
</tr>
<tr>
<td>§ 42</td>
<td>—Sample questions to be asked of plaintiff in products liability action</td>
</tr>
<tr>
<td>§ 43</td>
<td>—Sample questions to be asked of defense expert</td>
</tr>
<tr>
<td>§ 44</td>
<td>Requests for admissions—Admissions on part of defendant physician</td>
</tr>
<tr>
<td>§ 45</td>
<td>—Admissions on part of plaintiff</td>
</tr>
<tr>
<td>§ 46</td>
<td>Production of documents</td>
</tr>
<tr>
<td>§ 47</td>
<td>Physical examinations</td>
</tr>
</tbody>
</table>

V. PROOF OF MALPRACTICE INVOLVING COMPOUNDED DRUG

A. INTRODUCTION

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 48</td>
<td>Model trial factual situation</td>
</tr>
<tr>
<td>§ 49</td>
<td>Illustrative testimony</td>
</tr>
</tbody>
</table>

B. PLAINTIFF’S TESTIMONY [DIRECT EXAMINATION]

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 50</td>
<td>Identification of witness; relationship to decedent</td>
</tr>
</tbody>
</table>
§ 51 Patient’s medical history; low back pain
§ 52 Patient’s visit to defendant physician; steroid injection recommendation
§ 53 Steroid injection
§ 54 Patient’s death
§ 55 Discovery of fungus in steroid injection
§ 56 Damages

C. DEFENDANT PHYSICIAN’S TESTIMONY
[CROSS-EXAMINATION]
§ 57 Physician negligent; did not confirm sterility assurance of compounding pharmacy or steroid
§ 58 Pharmacy negligent; dispensed steroid contaminated with fungus; FDA warning letter

VI. PROOF OF PRODUCTS LIABILITY FOR INJURY FROM COMPOUNDED DRUG

A. INTRODUCTION
§ 59 Model trial factual situation
§ 60 Illustrative testimony

B. PLAINTIFF’S TESTIMONY [DIRECT EXAMINATION]
§ 61 Identification of witness
§ 62 Plaintiff’s medical history; problems with excess weight
§ 63 Plaintiff’s consultation with physician about bariatric surgery
§ 64 Physician recommendation of diet and exercise
§ 65 Physician recommends one-a-day compounded diet pill
§ 66 Prescription instructs patient to take 10 pills per day
§ 67 Stroke one week after starting prescription
§ 68 Hospital discovers excessive prescription of compounded diet drug
§ 69 Physical limitations as result of stroke
§ 70 Inability to work because of stroke
§ 71 Medical expenses
§ 72 Other damages; physical and emotional problems

420
C. DEFENDANT PHARMACY REPRESENTATIVE TESTIMONY [CROSS-EXAMINATION]

§ 73 Compounded diet drug was unreasonably dangerous and defective

§ 74 Compounded diet drug dispensed with wrong dosage instruction

§ 75 Stroke result of compounding pharmacy’s products liability

Scope

This article discusses proof of liability on the part of a physician, a pharmacist, or a pharmacy for injury caused by the ingestion or application of a compounded drug. The issue of liability for injury caused by a compounded drug may arise in a civil action for medical malpractice or products liability.

Research References

West’s Key Number Digest
Health ⇛ 800; Products Liability ⇛ 114, 225

A.L.R. Library
A.L.R. Index, Drugs and Narcotics; Drugstores and Druggists; Physicians and Surgeons
West’s A.L.R. Digest, Health ⇛ 800, 982; Products Liability ⇛ 114, 225

Products Liability: Necessity and Admissibility of Expert or Opinion Evidence as to Adequacy of Warning Provided to User of Prescription Drugs, 25 A.L.R.7th Art. 8


Civil liability of pharmacists or druggists for failure to warn of potential drug interactions in use of prescription drug, 79 A.L.R. 5th 409

Liability of pharmacist who accurately fills prescription for harm resulting to user, 44 A.L.R.5th 393

Liability of manufacturer or seller for injury or death allegedly caused by failure to warn regarding danger in use of vaccine or prescription drug, 94 A.L.R.3d 748

Liability of manufacturer or seller for injury caused by drug or medicine sold, 79 A.L.R.2d 301

Federal Preemption of State Common-Law Products Liability Claims Pertaining to Drugs, 70 A.L.R. Fed. 2d 69

421